(Undated) — Newly released clinical trial results may challenge some of the concerns raised about the Johnson and Johnson COVID-19 booster shot.
It finds tens of thousands of patients in South Africa who took the J&J booster shot actually achieved strong protection against serious illness from the COVID-19 Omicron variant.
According to Fox News, a study was done with tens of thousands of healthcare workers in South Africa who had received the J&J booster shot.
Those patients were compared to a group of un-vaccinated people in the local population.
The trial showed the J&J-boosted healthcare workers had an 85% lower risk of becoming seriously ill or hospitalized from the Omicron variant of COVID-19.
The U.S. Centers for Disease Control and Prevention has recently announced publicly it recommends the Pfizer and Moderna vaccines over the Johnson and Johnson shot due to concerns about blood clots.
It’s important to note the new clinical trial about the J-and-J booster shot has not been peer reviewed.
BACKGROUND:
Published by Reuters 12/27/2021 @ 8:31 a.m.
ZURICH (Reuters) – Swiss drugs regulator Swissmedic said on Monday it approved booster doses for Johnson & Johnson’s COVID-19 vaccine in people 18 years and older who have received a first vaccination.
The second dose of the vaccine can be administered, at the earliest, two months after the first dose, Swissmedic said in a statement.
It said mixed vaccinations with the J&J shot being administered six months after the second dose of Pfizer/BioNTech’s or Moderna’s mRNA vaccines were also authorised.
(Reporting by Silke Koltrowitz, Editing by Miranda Murray)
Published by Reuters 12/15/2021 @ 7:06 p.m.
WASHINGTON (Reuters) -A U.S. Centers for Disease Control and Prevention advisory panel will meet on Thursday to consider possible limits on the use of the Johnson & Johnson COVID-19 vaccine because of continued blood clot issues, the Washington Post reported on Wednesday.
The CDC’s Advisory Committee on Immunization Practices will be presented new data that appears to show the rate of clots in people who received the Johnson & Johnson vaccine has increased since April, the Post reported, citing clinicians familiar with the agenda.
Use of the vaccine in the United States was paused for 10 days in April to investigate extremely rare but potentially deadly clots, mostly in young and middle-aged women.
There have been about nine deaths related to the issue, the Post said, citing an unnamed federal official.
The CDC did not immediately respond to a request from Reuters for comment on the Post report.
(Reporting by Eric Beech; Editing by Christopher Cushing and Peter Cooney)
Comments